ReviewCurrent opinion in infectious diseases2009
Pediatric antifungal agents.
Review in Current opinion in infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 30 citations in OpenAlex.
- Sensitive bioluminescence imaging of cryptococcosis inVirulence · 2024Article
- Advances of liposomal mediated nanocarriers for the treatment of dermatophyte infections.Heliyon · 2023Review
- Clinical Pharmacology Studies in Critically Ill Children.Pharmaceutical research · 2017Review
- Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Observational
- Advances in the treatment of invasive neonatal candidiasis.Expert opinion on pharmacotherapy · 2015Review
- Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clinical pharmacokinetics · 2014Review
- Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.Pharmaceutics · 2011Article
- Voriconazole plasma levels in children are highly variable.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIn immunocompromised hosts, invasive fungal infections are common and fatal. In the past decade, the antifungal armamentarium against invasive mycoses has expanded greatly. The purpose of the present report is to review the most recent literature addressing the use of antifungal agents in children. RECENT
findingsMost studies evaluating the safety and efficacy of antifungal agents are limited to adults. However, important progress has been made in describing the pharmacokinetics and safety of newer antifungal agents in children, including the echinocandins. SUMMARY: Dosage guidelines for newer antifungal agents are currently based on adult and limited pediatric data. Because important developmental pharmacology changes occur throughout childhood impacting the pharmacokinetics of these agents, antifungal studies specifically designed for children are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.